SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers

Study of the Mechanisms Leading to Increased Hemoglobin Levels and of the Cardiorenal Response in Type 2 Diabetic Patients With Recent Initiation of SGLT2 Inhibitors.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05408936

Acronym

SGLT2HgB

Enrollment

Registered

2022-06-07

Start date

2022-06-03

Completion date

2024-06-01

Last updated

2024-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

SGLT2 inhibitors, hemoglobin, NTproBNP, ketones

Brief summary

Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function. The study enrolls type 2 diabetic patients in whom the introduction of a SGLT2 inhibitor is deemed necessary as part of their routine treatment during their visit to our outpatient diabetes unit. A whole blood, a serum and a urine sample is obtained before and one month after the initiation of treatment with a SGLT2 inhibitor.

Interventions

DRUGSGLT2 inhibitor

Patients receive an SGLT2 inhibitor as part of theirn routine care.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* type 2 diabetes * Hba1C\>7% on their current treatment * introduction of SGLT2 inhibitor as part of their routine care

Exclusion criteria

* eGFR\<60 ml/min

Design outcomes

Primary

Measure	Time frame
Hemoglobin	0-1-3 months
Erythropoetin	0-1-3 months
NT-proBNP	0-1-3 months

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026